National Cancer Institute (NCI), 9000 Rockville Pike
Welcome,         Profile    Billing    Logout  
 60 Trials 
80 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mackall, Crystal L
NCT02304458 / 2014-005674-11: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Completed
1/2
140
Canada, US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
09/21
03/23
NCT05642455: SPEARHEAD-3 Pediatric Study

Recruiting
1/2
20
US
Afamitresgene autoleucel
Adaptimmune
Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma, Osteosarcoma
10/26
07/38
NCT03241940: Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Recruiting
1
50
US
Chimeric Antigen Receptor T-Cell Therapy, CAR T-cell therapy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Questionnaire Administration
Crystal Mackall, MD
B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
08/25
08/35
NCT05474378: B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

Recruiting
1
39
US
B7-H3CART, B7H3-CAR T
Crystal Mackall, MD, California Institute for Regenerative Medicine (CIRM)
Brain and Nervous System
08/25
08/25
NCT04196413: GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)

Recruiting
1
54
US
GD2 CAR T cells, Fludarabine, Cyclophosphamide
Crystal Mackall, MD, California Institute for Regenerative Medicine (CIRM), CureSearch, National Institutes of Health (NIH)
Glioma of Spinal Cord, Glioma of Brainstem
07/28
07/43
Rosenberg, Steven A
NCT01174121: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Recruiting
2
332
US
Young TIL, Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda)
National Cancer Institute (NCI)
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
12/24
12/24
NCT01319565: Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Active, not recruiting
2
102
US
Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
National Cancer Institute (NCI)
Metastatic Melanoma, Skin Cancer
06/25
06/26
NCT03412877: Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Recruiting
2
270
US
Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA )
National Cancer Institute (NCI)
Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Neuroendocrine Tumors, Multiple Myeloma
03/27
03/28
NCT04102436: Non-Viral TCR Gene Therapy

Withdrawn
2
210
US
Fludarabine, Cyclophosphamide, Aldesleukin, Sleeping Beauty Transposed PBL
National Cancer Institute (NCI)
Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Ovarian Cancer
03/24
03/24
NCT06253520: Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Recruiting
1
210
US
Aldesleukin, Fludarabine, Cyclophosphamide, KRAS TCR-Transduced PBL, GRT-C903/GRT-R904
National Cancer Institute (NCI)
Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
06/31
06/33
NCT00923026: Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

Enrolling by invitation
N/A
1000
US
National Cancer Institute (NCI)
Melanoma, Adenocarcinoma, Carcinoma NOS, Neuroendocrine Tumors
 
 
NCT00001823: Evaluation for NCI Surgery Branch Clinical Research Protocols

Recruiting
N/A
7000
US
National Cancer Institute (NCI)
Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer
 
 
NCT00068003: Harvesting Cells for Experimental Cancer Treatments

Enrolling by invitation
N/A
7000
US
Anti-CD19 CAR PBL
National Cancer Institute (NCI)
Melanoma, Gastrointestinal Cancer, Metastatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer
 
 
NCT05600933: Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

Enrolling by invitation
N/A
1200
US
National Cancer Institute (NCI)
Solid Tumors, Hematologic Malignancy, Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, Melanoma, Pre-Malignancy, Lung Cancer
06/33
06/33
Widemann, Brigitte C
NCT00652990: Sirolimus to Treat Plexiform Neurofibromas in Patients With Neurofibromatosis Type I

Active, not recruiting
2
18
US
Sirolimus
University of Alabama at Birmingham, National Cancer Institute (NCI)
Neurofibromatosis Type 1, Plexiform Neurofibromas, Paraspinal Plexiform Neurofibromas
08/14
08/14
NCT00678951: Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults

Recruiting
2
90
US
PEG-interferon alfa-2b, MRI
National Cancer Institute (NCI)
Neurofibromatosis Type 1, Plexiform Neurofibroma
01/16
01/16
NCT02644512: MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Recruiting
2
50
US
Selumetinib
National Cancer Institute (NCI)
Neurofibromatosis 1, Plexiform Neurofibromas
06/19
06/19
NCT03105258: Selumetinib Pilot Study for Cutaneous Neurofibromas

Not yet recruiting
2
24
US
Selumetinib, AZD6244 Hydrogen Sulfate
University of Alabama at Birmingham, National Cancer Institute (NCI)
Neurofibromatosis Type 1, Cutaneous Neurofibroma
12/20
12/21
NCT03433183: SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Completed
2
21
US
Selumetinib, AZD6244, Sirolimus, Rapamycin
Sarcoma Alliance for Research through Collaboration, United States Department of Defense, AstraZeneca
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
06/22
10/23
SPRINT, NCT02407405: MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Checkmark From SPRINT trial in NF1-related plexiform neurofibromas at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: From SPRINT trial in NF1-related plexiform neurofibromas at ASCO 2018 [screenshot]
Active, not recruiting
2
36
US
Selumetinib
National Cancer Institute (NCI)
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN)
01/25
01/25
NF111, NCT04544007: A Phase II Trial of Poly-ICLC for Low-Grade Gliomas

Recruiting
2
20
US
Poly ICLC
University of Alabama at Birmingham, Children's Healthcare of Atlanta, Children's Hospital Los Angeles
NF1, Low-grade Glioma
02/26
02/27
NCT04872543: A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Recruiting
2
25
US
ASTX727
Memorial Sloan Kettering Cancer Center, Astex Pharmaceuticals, Inc.
Malignant Peripheral Nerve Sheath Tumors (MPNST)
04/26
04/26
SPRINT, NCT01362803: AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Checkmark In children with NF1
Mar 2020 - Mar 2020: In children with NF1
Checkmark For pediatric patients with inoperable NF1(neurofibromatosis type 1)-related PNs [SPRINT]
Nov 2018 - Nov 2018: For pediatric patients with inoperable NF1(neurofibromatosis type 1)-related PNs [SPRINT]
Checkmark Last patient dosing in P2 trial for pediatric neurofibromatosis type 1
More
Active, not recruiting
1/2
99
US
AZD6244
National Cancer Institute (NCI)
Neurofibromatosis 1, Neurofibromatosis Type 1, NF1, Neurofibroma, Plexiform
01/25
01/30
NCT00924196: Natural History Study of Patients With Neurofibromatosis Type I

Active, not recruiting
N/A
259
US
National Cancer Institute (NCI)
Neurofibromatosis Type 1, Malignant Peripheral Nerve Sheath Tumor, Plexiform Neurofibroma, Optic Glioma, Neurofibroma
 
 
NCT06222203: Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

Recruiting
N/A
225
US
National Cancer Institute (NCI)
Neurofibromatosis 1, Nerve Sheath Neoplasms
12/34
12/35
NCT03910465: Children and Adults With Chordoma

Recruiting
N/A
300
US
National Cancer Institute (NCI)
Chordoma
12/29
12/29
Bates, Susan E
TIGeR-PaC, NCT03257033: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Recruiting
3
190
Europe, US
Gemcitabine, Gemzar, nab-paclitaxel, Abraxane, RenovoCath
RenovoRx
Locally Advanced Pancreatic Cancer
06/26
09/26
EA5181, NCT04092283: Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Active, not recruiting
3
660
US, RoW
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt
National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
12/28
12/28
Lung-Map Screening Study, NCT03851445: Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Recruiting
2/3
10000
US
Screening Platform
SWOG Cancer Research Network, National Cancer Institute (NCI)
Previously Treated Non-Small Cell Lung Cancer
01/29
01/29
NCT03264404: Azacitidine and Pembrolizumab in Pancreatic Cancer

Active, not recruiting
2
36
US
Pembrolizumab, Keytruda, Azacitidine, Vidaza
Susan E. Bates
Pancreas Cancer
10/21
01/25
NCT05241249: Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

Recruiting
2
37
US
Bethanechol, Bethanechol chloride tablet, Gemcitabine, nab-paclitaxel
Susan E. Bates
Pancreas Cancer
01/25
01/25
NCT04533451: Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Active, not recruiting
2
101
US
Pembrolizumab, Pemetrexed, Carboplatin, Comprehensive Geriatric Assessment, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
10/23
05/27
NCT04068194: Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Recruiting
1/2
101
US
Avelumab, Bavencio, MSB 0010718C, MSB-0010718C, MSB0010718C, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib
National Cancer Institute (NCI)
Cholangiocarcinoma, Gallbladder Carcinoma, Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
12/25
12/25
NCT03572283: Bethanechol Prior to Pancreatic Surgery

Active, not recruiting
1
17
US
Bethanechol, Bethanechol chloride tablet
Columbia University
Pancreas Cancer
07/23
08/24
NCT02631733: Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Active, not recruiting
1
48
US
Ferumoxytol, Feraheme, Ferumoxytol Non-Stoichiometric Magnetite, Irinotecan Sucrosofate, inotecan Hydrochloride as Sucrosulfate Salt Form Liposomal Formulation, Irinotecan Liposome, Irinotecan Sucrosofate Liposome, Irinotecan Sucrosofate-containing Pegylated Liposomal Formulation, MM 398, MM-398, MM398, nal-IRI, Nanoliposomal Irinotecan, Nanoliposomal Irinotecan as Sucrosofate, Nanoparticle Liposome Formulation of Irinotecan, Onivyde, PEP 02, PEP-02, PEP02, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Malignant Solid Neoplasm
07/24
07/24
Figg, William D
NCT03436745: The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Completed
1
11
US
Zolpidem
National Cancer Institute (NCI)
Prostatic Neoplasms
01/24
01/24
NCT00341939: Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data

Completed
N/A
484
US
National Cancer Institute (NCI)
Prostate Cancer, Breast Cancer, Cutaneous T-Cell Lymphoma, Lung Cancer, Melanoma
06/24
06/24
NCT00026663: Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance

Completed
N/A
86
US
National Cancer Institute (NCI)
Renal Cell Carcinoma, Lung Carcinoma, Cervical Carcinoma
06/24
06/24
NCT01441089: Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

Recruiting
N/A
1100
US
National Cancer Institute (NCI)
Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
 
 
NCT00923221: Collection of Blood From Patients With Prostate Cancer

Recruiting
N/A
1000
US
National Cancer Institute (NCI)
Cancer Of Prostate, Prostate Cancer, Prostatic Neoplasms, Metastatic Prostate Cancer, Prostate
 
 
NCT02706652: Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients

Enrolling by invitation
N/A
900
US
National Cancer Institute (NCI)
Cancer
12/26
12/26
NCT02810405: Collection of Tissue Blocks or Slides From Patients With Cancer

Completed
N/A
191
US
National Cancer Institute (NCI)
Tumor, Carcinogens, Neoplasm, Benign, Benign Neoplasms, Cancer
08/24
08/24
NCT02154022: Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity

Enrolling by invitation
N/A
100
US
National Cancer Institute (NCI)
Cancer, Solid Tumors, Neoplasm
05/29
05/30
Greene, Mark H
NCT00954239: Impact of Testing Positive for the BRCA1 or BRCA2 Mutation in Young Women Who Are BRCA1 or BRCA2 Mutation Carriers

Recruiting
N/A
50
US
telephone-based intervention, questionnaire administration, psychosocial assessment and care
National Cancer Institute (NCI)
brca1 Mutation Carrier, brca2 Mutation Carrier, Sexuality and Reproductive Issues
12/10
 
Wentzensen, Nicolas
NCT04609072: Connect for Cancer Prevention Study (Connect)

Recruiting
N/A
200000
US
National Cancer Institute (NCI)
Cancer, General Research Use
12/70
12/70
Fojo, Antonio
DORA, NCT03574571: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
NCT03839498: Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Recruiting
2
25
US
Axitinib, AG-013736
Columbia University, Pfizer
Pheochromocytoma, Paraganglioma
12/23
01/24
LAMPARA, NCT03946527: LAnreotide in Metastatic Pheochromocytoma / PARAganglioma

Recruiting
2
40
US
Lanreotide, Somatuline Depot
Antonio Fojo, Ipsen
Paraganglioma, Pheochromocytoma
12/23
12/23
CHOMP, NCT04104893: A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

Recruiting
2
30
US
Pembrolizumab, Keytruda
VA Office of Research and Development, Merck Sharp & Dohme LLC
Metastatic Castration Resistant Prostate Cancer
03/25
12/25
BRACeD, NCT04038502: Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Recruiting
2
100
US
Carboplatin, Paraplatin, Olaparib, Lynparza
VA Office of Research and Development
Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
08/25
08/25
NCT03127774: Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma

Recruiting
2
30
US
Cisplatin, Platinol, Sodium thiosulfate, Sodium thiosulfate injection, Cytoreductive surgery, Cytoreductive debulking surgery
Columbia University
Adrenocortical Carcinoma, Peritoneal Carcinomatosis
12/25
12/25
Goldstein, Alisa M
NCT00040352: Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

Recruiting
N/A
3000
US
National Cancer Institute (NCI)
Melanoma, Dysplastic Nevus Syndrome
 
 
NCT01200680: Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes

Recruiting
N/A
300
US
National Cancer Institute (NCI)
Genes, Sporadic Chordoma
 
 
Cortner, Janelle
NCT00339911: Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-Frederick

Enrolling by invitation
N/A
1200
US
National Cancer Institute (NCI)
Healthy Donors
10/30
10/30
Murphy, Gwen A
GEM, NCT06085677: The Gastric HormonE BioMarkers of Preneoplastic Lesions Study

Not yet recruiting
N/A
600
NA
Imperial College London, University College, London, University of Oxford, University of Copenhagen
Stomach Neoplasm, Chronic Atrophic Gastritis, Intestinal Metaplasia
09/24
09/24
Abnet, Christian
NCT00450788: Esophageal Cancer in Northeastern Iran

Completed
N/A
50045
RoW
National Cancer Institute (NCI)
Esophageal Cancer, GI Disease
 
 
NCT00342654: Nutrition Intervention Trials in Linxian Follow-up Study

Enrolling by invitation
N/A
34000
RoW
National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
12/24
12/24
NCT00341523: Early Detection of Esophageal Cancer

Terminated
N/A
6864
RoW
National Cancer Institute (NCI)
Esophageal Neoplasms, Stomach Neoplasms, Endoscopy, Gastrointestinal, Digestive System Endoscopic Surgical Procedures, Cytology
04/24
04/24
NCT00340405: Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China

Active, not recruiting
N/A
9759
RoW
National Cancer Institute (NCI)
Lung Cancer
12/40
12/40
Sinha, Rashmi
NCT04750915: NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 Data

Active, not recruiting
N/A
566398
US
National Cancer Institute (NCI)
Cancer, Mortality, Chronic Diseases
12/50
12/50
Beane-Freeman, Laura
NCT00352924: Agriculture Health Study

Active, not recruiting
N/A
89655
US
National Cancer Institute (NCI), Environmental Protection Agency (EPA)
Prostate Cancer, Pesticide Exposures, Lymphoma, Multiple Myeloma
 
 
McMaster, Mary L
NCT00039676: Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

Active, not recruiting
N/A
1836
US
National Cancer Institute (NCI)
Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Hodgkin Disease, NonHodgkin Lymphoma, Mixed Lymphoproliferative Disease
 
 
Silverman, Debra
NCT00342264: A Nested Case-Control Study of Lung Cancer and Diesel Exhaust Among Non-Metal Miners

Completed
N/A
1187
US
National Cancer Institute (NCI)
Lung Cancer
04/24
04/24
Morton, Lindsay M
NCT00342797: Retinoblastoma Biomarker Study

Completed
N/A
2136
US
National Cancer Institute (NCI)
Retinoblastoma, Melanoma, Sarcoma
03/24
03/24
Benson, Gretchen
NCT00475761: Breast Mammogram and Tissue Study

Active, not recruiting
N/A
466
US
National Cancer Institute (NCI)
Breast Neoplasms
 
 
T2T, NCT06471036: Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?

Recruiting
N/A
400
US
Care Champion Intervention
Duke University, Amgen
ASCVD, LDL-C
06/25
02/26
Lan, Qing
NCT04943913: Study on TIL for the Treatment of Brain Glioma

Recruiting
1
50
RoW
Tumor Infiltrating Lymphocytes (TIL)
Shanghai Juncell Therapeutics, Second Affiliated Hospital of Soochow University
Glioma
12/24
05/25
SJWKtumor001, NCT05752877: Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma

Recruiting
N/A
12
RoW
Targeted IL-13 Rα2 UCAR-T cell injection, Targeted B7-H3 UCAR-T cell injection
Second Affiliated Hospital of Soochow University, Soochow T-Maximun Biotechnology Co. LTD
Advanced Glioma, Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy
04/26
04/26
Cowen, Edward W
NCT00001506: Evaluation and Treatment of Patients With Dermatologic Diseases

Recruiting
N/A
500
US
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Dermatologic Diseases, Systemic Diseases With Cutaneous Manifestations
 
 
Kreimer, Aimee R
NCT03180034: Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study

Enrolling by invitation
4
28000
RoW
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Adacel, Daptacel, Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine, DTaP, Infanrix, Tripedia, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine
National Cancer Institute (NCI), Bill and Melinda Gates Foundation
Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
08/25
08/25
PRISMA, NCT05237947: Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The ESCUDDO Trial

Active, not recruiting
4
5000
RoW
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Adacel, Daptacel, Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine, DTaP, Infanrix, Tripedia, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine
National Cancer Institute (NCI)
Cervical Carcinoma, Human Papillomavirus Infection
05/26
05/26
PRIMAVERA-ESCUDDO, NCT03728881: Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the Trial

Completed
3
1240
RoW
Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine, Gardasil, Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine, quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, V501, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine
National Cancer Institute (NCI)
Human Papillomavirus-Related Cervical Carcinoma
09/22
04/24
NCT00867464: Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls

Active, not recruiting
N/A
8670
RoW
Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis, Long-term Follow-up, long term follow-up (clinical study), LTFU, Questionnaire Administration
National Cancer Institute (NCI)
Anal Carcinoma, Cervical Carcinoma, Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma, Oral Cavity Carcinoma
12/23
12/23
ESCUDDO-CVT, NCT03309033: Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), Study

Active, not recruiting
N/A
991
RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Questionnaire Administration
National Cancer Institute (NCI)
Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
02/26
02/26
Park, Deric M
PROTECT, NCT04469075: Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Recruiting
2
58
US
Clindamycin Phosphate, Triamcinolone Acetonide
Memorial Sloan Kettering Cancer Center
Glioblastoma, Recurrent Glioblastoma, Skin Toxicity
07/25
07/25
S22-11168, NCT06359379: Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Recruiting
2
54
US
Ropidoxuridine, 5-iodo-2-pyrimidinone-2'-deoxyribose
Shuttle Pharmaceuticals, Inc.
Glioblastoma, IDH-wildtype
08/26
02/27
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
NCT05859334: Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Recruiting
2
35
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Optical Coherence Tomography, OCT, Optical Coherence Tomography (OCT)
National Cancer Institute (NCI)
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma
10/26
10/26
Freedman, Neal D
NCT00339495: Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial

Active, not recruiting
N/A
154900
US
National Cancer Institute (NCI)
Cancer, Death
12/25
12/25
Khincha, Payal P
NCT01443468: Clinical and Genetic Studies of Li-Fraumeni Syndrome

Recruiting
N/A
5000
US
National Cancer Institute (NCI)
Li-Fraumeni Syndrome, Neoplasms, Tp53 Mutations
 
 
Giles, Amber J
No trials found

Download Options